General Proximity
General Proximity is a biotechnology platform company pioneering the next generation of induced proximity medicines. Its OmniTAC platform enables precise modification of disease-driving proteins, opening therapeutic opportunities for previously undruggable targets. The company focuses on treatments for cancer, cardiometabolic disease, neurodegeneration, and longevity.
Buy Funded Startups lists
Funding Round: Seed
Funding Amount: $16M
Date: 03-Jan-2025
Investors: Aydin Senkut at Felicis, Y Combinator, Jim Dahl (Rock Creek), age1, Modi Ventures, Wilson Sonsini
Markets: Biotechnology, Oncology, Cardiometabolic Disease, Neurodegenerative Diseases, Longevity, Medical
HQ: San Francisco, California, United States
Founded: 2019
Website: https://www.generalproximity.bio/
LinkedIn: https://www.linkedin.com/company/generalproximity
Twitter: https://twitter.com/proxbio
Crunchbase: https://www.crunchbase.com/organization/general-proximity-650b
Leave a Comment
Comments
No comments yet.